tellimagrandin II: isolated from Filipendula palmata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Filipendula | genus | A plant genus of the family ROSACEAE. Members contain TANNINS.[MeSH] | Rosaceae | The rose plant family in the order ROSALES and class Magnoliopsida. They are generally woody plants. A number of the species of this family contain cyanogenic compounds.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 151590 |
SCHEMBL ID | 618555 |
MeSH ID | M0448598 |
Synonym |
---|
beta-d-glucopyranose, cyclic 4,6-((1s)-4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1,2,3-tris(3,4,5-trihydroxybenzoate) |
tellimagrandin ii |
81571-72-4 |
.beta.-d-glucopyranose, cyclic 4,6-[(1s)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] 1,2,3-tris(3,4,5-trihydroxybenzoate) |
beta-d-glucopyranose, cyclic 4,6-(4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1,2,3-tris(3,4,5-trihydroxybenzoate) |
SCHEMBL618555 |
1,2,3-tri-o-galloyl-4,6-(s)-hexahydroxydiphenoyl-b-d-glucopyranose |
[3,4,5,21,22,23-hexahydroxy-8,18-dioxo-12,13-bis[(3,4,5-trihydroxybenzoyl)oxy]-9,14,17-trioxatetracyclo[17.4.0.02,7.010,15]tricosa-1(23),2,4,6,19,21-hexaen-11-yl] 3,4,5-trihydroxybenzoate |
D85207 |
MS-31750 |
DTXSID201002061 |
HY-N9386 |
CS-0159630 |
AKOS040758365 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (60.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.66) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |